
Galina Ramenskaya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1810856/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety assessment of a new anti-tuberculosis drug in silico and with the participation of healthy volunteers. Farmakogenetika I Farmakogenomika, 2022, , 42-47.	0.0	О
2	An approach to the quantitative determination of endogenous substances in biological fluids by a chromatographic method using a mathematical apparatus. Pharmacokinetics and Pharmacodynamics, 2022, , 11-18.	0.1	1
3	Organization of Hygienic Monitoring of Working Area Air Pollution by Particulates in Pharmaceutical Industries (Review). Drug Development and Registration, 2022, 11, 165-173.	0.2	О
4	Development and Validation of the HPLC Method for Quantification of the Innovative Drug DD217, Factor Xa Inhibitor, in Rat Plasma for a Pharmacokinetic Study. Drug Development and Registration, 2022, 11, 197-206.	0.2	0
5	Insights into the Cardiotoxic Effects of Veratrum Lobelianum Alkaloids: Pilot Study. Toxins, 2022, 14, 490.	1.5	1
6	Quantitative Content Parameter in the Standardization of Veratrum Aqua, Veratrum Lobelianum Bernh. Based Drug. Drug Development and Registration, 2021, 10, 107-113.	0.2	2
7	ĐϔĐ»Đ°Đ¼Đ,Ñ€Đ¾Đ²Đ°Đ½Đ,е Đ, Đ¾Ñ†ĐµĐ½ĐºĐ° Đ,ÑÑлеĐѢ¾Đ²Đ°Đ½Đ,Đ¹ бĐ,Đ¾ÑĐºĐ²Đ,Đ²€)°Ð»Ð µÐ ½Ñ	I,Ð1⁄2Ð34ÑÑ,Ð
8	Veratrum Alkaloid Determination in Four Cases of Veratrum Aqua Poisonings. Journal of Analytical Toxicology, 2021, , .	1.7	9
9	Planning and Evaluation of Bioequivalence Studies of Drugs with Nonlinear Pharmacokinetics. Pharmaceutical Chemistry Journal, 2021, 55, 1-5.	0.3	О
10	Characterisation of α-amylase inhibitors in marigold plants via bioassay-guided high-performance thin-layer chromatography and attenuated total reflectance–Fourier transform infrared spectroscopy. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1173, 122676.	1.2	7
11	A new integrated HPTLC - ATR/FTIR approach in marine algae bioprofiling. Journal of Pharmaceutical and Biomedical Analysis, 2020, 189, 113488.	1.4	13
12	Planning and Evaluation of Bioequivalence Studies of Lopinavir/Ritonavir Preparations. Pharmaceutical Chemistry Journal, 2020, 53, 1101-1105.	0.3	1
13	Antimicrobial Activity of Lyophilized Aqueous Extract from Caragana Jubata (Pall.) Poir Pharmaceutical Chemistry Journal, 2020, 54, 290-292.	0.3	1
14	The Mechanism of Action of Ethoxidol on Oxidative Stress Indices in Heart Failure and Hypotension. Sovremennye Tehnologii V Medicine, 2020, 12, 67.	0.4	9
15	Use of endogenous cholesterol and its metabolite as markers of cyp450 metabolic activity. Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR, 2020, 26, 93-97.	0.1	0
16	Determination of genotoxic impurities in pharmaceutical substances. Farmatsiya-Moscow, 2020, 69, 10-16.	0.0	0
17	Anti-tuberculosis activity in the presence of drug resistance as a rationale for prospect use of thiosonide. Siberian Medical Journal, 2020, 35, 125-132.	0.3	0
18	Double electrooxidative C–H functionalization of (het)arenes with thiocyanate and 4-nitropyrazolate ions. Mendeleev Communications, 2019, 29, 334-336.	0.6	17

#	Article	IF	CITATIONS
19	Lipidomic analysis as a tool for identifying susceptibility to various skin diseases. MedChemComm, 2019, 10, 1871-1874.	3.5	4
20	An improved extraction protocol for therapeutic dabigatran monitoring using HPLC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1130-1131, 121808.	1.2	4
21	Assessment of in Vitro Comparative Dissolution Kinetics of Moxonidine Products as a Factor Potentially Determining Effectiveness of Antihypertensive Treatment. Rational Pharmacotherapy in Cardiology, 2019, 14, 951-957.	0.3	2
22	Analytical Strategies in Lipidomics for Discovery of Functional Biomarkers from Human Saliva. Disease Markers, 2019, 2019, 1-11.	0.6	17
23	Comparison of FDA (2018) and EAEU Regulatory Requirements for Bioanalytical Method Validation. Pharmaceutical Chemistry Journal, 2019, 53, 759-765.	0.3	3
24	Comparison of Approaches to Determining N-Nitrosodimethylamine Impurity in Valsartan Drug Substance By GC-MS Methods. Pharmaceutical Chemistry Journal, 2019, 53, 766-770.	0.3	3
25	Peptide-Based Therapeutics for Oncology. Pharmaceutical Medicine, 2019, 33, 9-20.	1.0	17
26	Đ¡Đ¾Đ²Ñ€ĐµĐ¼ĐµĐ½Đ½Ñ‹Đµ Ñ€ĐµĐ³ÑƒĐ»ÑŇ,Đ¾Ñ€Đ½Ñ‹Đµ Ñ,Ñ€ĐµĐ±Đ¾Đ²Đ°Đ½Đ,Ñ•FDA Đº Đ²Đ°Đ»	Ð Ð.Ð °Ñ†	Ð,₽,бÐ,Đ¾
27	ĐŸĐ»Đ°Đ½Đ,Ñ€Đ¾Đ²Đ°Đ½Đ,е Đ, Đ¾Ñ†ĐµĐ½ĐºĐ° Đ,ÑÑлеĐƊ¾Đ²Đ°Đ½Đ,Đ¹ бĐ,Đ¾ÑĐºĐ²Đ,Đ²Đ°Đ	» ĐquÐ 1∕2Ñ _;	нD34ÑÑ .
28	The role of interleukin-33 in pathogenesis of bronchial asthma. New experimental data. Biochemistry (Moscow), 2018, 83, 13-25.	0.7	23
29	Biologically Active Compounds in Aqueous Extracts of Caragana jubata (Pall.) Poir Pharmaceutical Chemistry Journal, 2018, 51, 1014-1020.	0.3	2
30	HPLC-MS/MS Method for Determining Dabigatran in Human Blood Serum. Pharmaceutical Chemistry Journal, 2018, 51, 1129-1137.	0.3	5
31	Planning and Assessment of Bioequivalence Studies of Darunavir Preparations. Pharmaceutical Chemistry Journal, 2018, 52, 771-775.	0.3	0
32	Potential Biological Activity and Chemical Composition of Caragana Jubata (Pall.) Poir. (Review). Pharmaceutical Chemistry Journal, 2018, 52, 531-535.	0.3	6

33	Development of an HPLC-MS/MS Method for Quantitative Determination of Rivaroxaban in Human Blood Serum. Pharmaceutical Chemistry Journal, 2018, 52, 372-377.	0.3	5
34	Phospholipase D: Its Role in Metabolic Processes and Development of Diseases. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2018, 12, 247-257.	0.2	0
35	Validated HPLC-MS/MS method for quantification of ethylmethylhydroxypyridine succinate in rat brain and its application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1096, 180-186.	1.2	1
36	Standardization of Thrombaptanib Drug Substance for Residual Organic Solvents. Pharmaceutical	0.3	1

Chemistry Journal, 2018, 52, 366-371.

#	Article	IF	CITATIONS
37	The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 127-137.	0.4	34
38	The application of the screening techniques for the purpose of chemical toxicological and forensic chemical analysis. Sudebno-Meditsinskaya Ekspertisa, 2018, 61, 31.	0.1	1
39	PLANNING AND EVALUATION OF BIOEQUIVALENCE STUDIES OF ATAZANAVIR PRODUCTS. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 2018, 8, 151-157.	0.1	0
40	Approaches to Pharmaceutical Analysis of Modern Peptide and Oligonucleotide Products as Illustrated by a Small Interfering RNA-Based Novel Therapeutic for the Treatment of Bronchial Asthma. BIOpreparations Prevention Diagnosis Treatment, 2018, 18, 184-190.	0.2	0
41	Parameters of vancomycin pharmacokinetics in postoperative patients with renal dysfunction: comparing the results of a pharmacokinetic study and mathematical modeling. Bulletin of Russian State Medical University, 2018, , 58-64.	0.3	0
42	ĐϔĐ°Ñ€Đ°Đ¼ĐμÑ,ры Ñ"Đ°Ñ€Đ¼Đ°ĐĐ¾Đ°Đ,Đ½ĐμÑ,Đ,ĐĐ, Đ²Đ°Đ½Đ₽Đ¾Đ¼Đ,цĐ,Đ½Đ° у Đ±Đ¾Đ	»Ñ ŒÐ ½Ñ	k Ñ. Ω Ñ•Đ¹∕₂а
43	A Comparative Dissolution Kinetics Test for Omeprazole-Containing Medicines, Reproducing Secretory and Motor-Evacuatory Impairments the Stomach of Patients with Acid-Dependent Diseases. Pharmaceutical Chemistry Journal, 2017, 51, 824-828.	0.3	0
44	A Brief Review of the FDA Dissolution Methods Database. Dissolution Technologies, 2016, 23, 6-10.	0.2	24
45	Pharmacokinetic Studies of the Innovative Antituberculosis Drug Thiozonide in Plasma. Pharmaceutical Chemistry Journal, 2015, 49, 147-150.	0.3	0
46	Selected Issues on Regulation of the Circulation of Non-Biological Complex Drugs. Pharmaceutical Chemistry Journal, 2015, 49, 213-219.	0.3	2
47	Development and Validation of a Method for Assay of the Original Antituberculosis Agent Thiozonide in Plasma for Pharmacokinetic Studies. Pharmaceutical Chemistry Journal, 2015, 49, 199-202.	0.3	1
48	Identification and Quantitative Determination of the Main Biologically Active Substances in Motherwort Herb by HPLC–Mass Spectrometry. Pharmaceutical Chemistry Journal, 2014, 48, 461-466.	0.3	9
49	Biologically Active Substances from European Guelder Berry Fruits. Pharmaceutical Chemistry Journal, 2014, 48, 332-339.	0.3	36
50	Development and validation of an ion-pair HPLC method for determination of perchlozone in blood plasma. Russian Chemical Bulletin, 2014, 63, 1255-1258.	0.4	0
51	Detection of acute overdose states by some antihypertensive drugs using gas chromatography-mass spectrometry. Journal of Analytical Chemistry, 2014, 69, 1337-1343.	0.4	5
52	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Piroxicam. Journal of Pharmaceutical Sciences, 2014, 103, 367-377.	1.6	32
53	Development and Validation of an LC/MS Method for Quantitative Determination of Thiamine in Blood Plasma. Pharmaceutical Chemistry Journal, 2013, 46, 742-744.	0.3	6
54	Analysis of reasons for the impossibility of creating Copaxone generics. Pharmaceutical Chemistry Journal, 2013, 46, 656-660.	0.3	4

GALINA RAMENSKAYA

#	Article	IF	CITATIONS
55	HPLC and UPLC for Determining Drugs in Blood (A Review). Pharmaceutical Chemistry Journal, 2013, 47, 225-230.	0.3	9
56	Synthesis and Antifungal Activity of Arylthiocyanates. Pharmaceutical Chemistry Journal, 2013, 47, 422-425.	0.3	51
57	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Ketoprofen. Journal of Pharmaceutical Sciences, 2012, 101, 3593-3603.	1.6	70
58	The influence of B-group vitamins on monooxygenase activity of cytochrome P450 3A4: Pharmacokinetics and electro analysis of the catalytic properties. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2012, 6, 87-93.	0.2	4
59	Assessment of the possibility of using comparative in vitro dissolution kinetics (biowaiver) instead of in vivo bioequivalence evaluation for establishing the interchanbeability of generic drugs. Pharmaceutical Chemistry Journal, 2011, 45, 107-109.	0.3	10
60	Modern approaches to the validation of the pharmacopoeial dissolution test. Pharmaceutical Chemistry Journal, 2011, 45, 183-186.	0.3	0
61	Essential biopharmaceutical properties of drugs at the gastrointestinal absorption stage (Review). Pharmaceutical Chemistry Journal, 2011, 45, 415-418.	0.3	2
62	Electroanalysis of Cytochrome P450 3A4 Catalytic Properties with Nanostructured Electrodes: The Influence of Vitamin B Group on Diclofenac Metabolism. BioNanoScience, 2011, 1, 46-52.	1.5	17
63	Evaluation of In Vitro Equivalence for Drugs Containing BCS Class II Compound Ketoprofen. Dissolution Technologies, 2011, 18, 26-29.	0.2	18
64	Molecular-biological problems of drug design and mechanism of drug action. Pharmaceutical Chemistry Journal, 2010, 44, 51-55.	0.3	0
65	Gas chromatographic analysis of short-chain fatty acids in the standardization of medicinal formulations based on bacterial substrates. Pharmaceutical Chemistry Journal, 2010, 44, 334-336.	0.3	9
66	Qualitative and quantitative analysis of a new lyophilized liposomal formulation of photodithazine. Pharmaceutical Chemistry Journal, 2010, 44, 337-340.	0.3	2
67	In Vitro Dissolution Kinetics of Amlodipine Tablets Marketed in Russia Under Biowaiver Conditions. Dissolution Technologies, 2010, 17, 20-22.	0.2	11
68	Modern approaches to quality evaluation of generic drugs for their registration (a review). Pharmaceutical Chemistry Journal, 2009, 43, 512.	0.3	3
69	Comparative in vitro dissolution testing of trimetazidine prolonged-release tablets. Pharmaceutical Chemistry Journal, 2009, 43, 677-679.	0.3	1
70	Comparative in vitro dissolution testing of indapamide prolonged-release tablets. Pharmaceutical Chemistry Journal, 2008, 42, 726-729.	0.3	1
71	Developing a method for the quantitative determination of the P-glycoprotein activity marker fexofenadine in blood plasma. Pharmaceutical Chemistry Journal, 2006, 40, 686-689.	0.3	4
72	Pharmacokinetic Study of the New Domestic Hypodermic Form of Naltrexone: Prodetoxon Depot Tablets. Pharmaceutical Chemistry Journal, 2005, 39, 1-3.	0.3	6

#	Article	IF	CITATIONS
73	Chromatographic Determination of Drugs and Their Metabolites for Phenotyping Cytochrome P-450 Isoenzymes. Pharmaceutical Chemistry Journal, 2005, 39, 108-111.	0.3	1
74	The Problem of Device Calibration for the Pharmacopoeial Drug Dissolution Test. Pharmaceutical Chemistry Journal, 2003, 37, 550-555.	0.3	0
75	Pheno- and genotyping the prescription of drugs metabolized by CYP2D6. Bulletin of Experimental Biology and Medicine, 2002, 134, 159-160.	0.3	2
76	Title is missing!. Pharmaceutical Chemistry Journal, 2001, 35, 535-537.	0.3	0